NCT03975231 is a Phase 1 clinical trial of Dabrafenib in BRAF NP_004324.2:p.V600E, sponsored by City of Hope Medical Center.

Who is sponsoring NCT03975231?

NCT03975231 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT03975231?

Interventions in NCT03975231: Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib.

What condition does NCT03975231 study?

NCT03975231 studies BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma.

Is NCT03975231 still recruiting?

NCT03975231 is currently recruiting now. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT03975231

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Recruiting now Phase 1 Last updated 8 April 2026

What this trial tests

Phase 1 trial testing Dabrafenib in BRAF NP_004324.2:p.V600E in 6 participants. Currently enrolling.

Timeline

14 September 2020

Primary endpoint
5 October 2027

5 October 2027

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	14 September 2020
Primary completion	5 October 2027
Estimated completion	5 October 2027
Sites	3 locations across United States

Drugs / interventions tested

Dabrafenib (dabrafenib) — full drug profile →
Intensity-Modulated Radiation Therapy
Trametinib (trametinib) — full drug profile →

Conditions studied

BRAF NP_004324.2:p.V600E — all drugs for BRAF NP_004324.2:p.V600E →
BRAF V600K Mutation Present — all drugs for BRAF V600K Mutation Present →
Thyroid Gland Anaplastic Carcinoma — all drugs for Thyroid Gland Anaplastic Carcinoma →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with BRAF NP_004324.2:p.V600E or BRAF V600K Mutation Present. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Radiation-induced tumor immune microenvironments and potential targets for combination therapy.
Guo S, Yao Y, Tang Y, Xin Z, et al · · 2023 · cited 136× · PMID 37208386 · DOI 10.1038/s41392-023-01462-z
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870
Anaplastic Thyroid Carcinoma: An Update.
Jannin A, Escande A, Al Ghuzlan A, Blanchard P, et al · · 2022 · cited 110× · PMID 35205809 · DOI 10.3390/cancers14041061
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.
Crispo F, Notarangelo T, Pietrafesa M, Lettini G, et al · · 2019 · cited 72× · PMID 31540406 · DOI 10.3390/cancers11091388
Novel Inhibitor-Based Therapies for Thyroid Cancer-An Update.
Ratajczak M, Gaweł D, Godlewska M. · · 2021 · cited 37× · PMID 34769260 · DOI 10.3390/ijms222111829
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
Avery TY, Köhler N, Zeiser R, Brummer T, et al · · 2022 · cited 31× · PMID 35965494 · DOI 10.3389/fonc.2022.931774
Molecular features of aggressive thyroid cancer.
Elia G, Patrizio A, Ragusa F, Paparo SR, et al · · 2022 · cited 26× · PMID 36605433 · DOI 10.3389/fonc.2022.1099280
Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer.
Sekihara K, Himuro H, Toda S, Saito N, et al · · 2024 · cited 9× · PMID 38927493 · DOI 10.3390/biomedicines12061286

Verify or expand the search:

Other trials of Dabrafenib

Trials testing the same drug.

NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
NCT07010393 — Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · Phase 4 · not yet recruiting
NCT06119789 — Precision Cancer Therapy in Rare Cancers · Phase 2 · recruiting
NCT06739395 — Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · Phase 2 · recruiting
NCT06475989 — Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · Phase 3 · recruiting

Other recruiting trials for BRAF NP_004324.2:p.V600E

Currently open trials in the same condition.

NCT04017650 — Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or · Phase 1, PHASE2 · active not recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03975231 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing